Phibro Animal Health Corporation (PAHC) To Go Ex-Dividend on June 3rd

Phibro Animal Health Corporation (NASDAQ:PAHC) announced a quarterly dividend on Tuesday, May 5th. Stockholders of record on Wednesday, June 3rd will be paid a dividend of 0.12 per share on Wednesday, June 24th. This represents a c) annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Wednesday, June 3rd.

Phibro Animal Health has a payout ratio of 23.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Phibro Animal Health to earn $3.28 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 14.6%.

Phibro Animal Health Trading Up 4.0%

Shares of PAHC stock opened at $58.50 on Thursday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 0.86 and a beta of 0.61. The stock has a 50-day moving average of $54.07 and a 200-day moving average of $46.48. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. Phibro Animal Health has a 1-year low of $19.00 and a 1-year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities research analysts forecast that Phibro Animal Health will post 3.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on PAHC. Citigroup began coverage on Phibro Animal Health in a research note on Wednesday, April 15th. They set a “neutral” rating and a $62.00 target price for the company. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 target price on Phibro Animal Health in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $42.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.